Syndromic testing

Syndromic Testing Benefits

Resolve diagnostic unknowns fast

We understand how challenging it can be to quickly and accurately diagnose infectious diseases. When a patient is ill and time is of the essence, how do you make sure you test for the right pathogen the first time?

That's exactly when syndromic testing really shines. Unlike traditional diagnostic methods, like bacterial culture and microscopy, syndromic testing uses multiplex PCR to test for several pathogens at once – and it only takes around an hour. The quick, comprehensive results of syndromic testing let you provide the best care possible for your patients.

The benefits of syndromic testing go beyond fast results
Syndromic testing can help eliminate the guesswork of diagnosing infectious diseases and help you make faster clinical decisions. This not only benefits your patients, but your institution as a whole. Many clinical publications show that syndromic testing can help diagnostic labs work smarter, support antimicrobial stewardship programs, improve patient outcomes and reduce overall healthcare costs.
Q-Solutions Magazine
Your compass for disease incidence and prevalence

Confidently navigate the ebb and flow of infectious diseases in your community – and beyond – with QIAsphere Insights. Track everything from pathogen diversity, to rates of co-detection, to Ct value measures. With QIAsphere Insights, the power of epidemiology is in your hands.

Syndromic testing article hub

Get the latest insights on syndromic testing for infectious diseases
Syndromic testing for respiratory infections

COVID-19 and influenza-like illnesses will converge this respiratory season. This will put an unprecedented burden on healthcare providers to quickly and accurately distinguish between different respiratory pathogens that often produce similar symptoms in patients. Visit our dedicated resource page to learn how we can support you with syndromic testing this respiratory season.

How does syndromic testing work?

Syndromic testing provides qualitative detection and identification of multiple viral, bacterial, fungal and/or parasitic pathogens in a sample using highly multiplexed real-time PCR. While older molecular methods required multiple different singleplex tests to be run, syndromic testing can provide results for more than 20 pathogens with just one multiplex test. This saves time and resources and increases lab efficiency.

How are pathogens detected in syndromic testing?

The real-time PCR reaction that mediates detection of pathogen targets in a patient sample involves four simple steps that take around one hour. In this simplified example, the specific pathogen target being detected is viral RNA.

What do syndromic test results look like?

Unlike traditional laboratory techniques, which can sometimes produce subjective results, syndromic testing provides a binary answer for pathogen detection: positive or negative.

Syndromic testing simplified

The easy-to-use QIAstat-Dx Analyzer makes syndromic testing especially straightforward. With less the one minute hands-on time – and no precision pipetting – you can get comprehensive results for more than 20 pathogens in around one hour.
QIAstat-Dx analyzer
Bring the accuracy of syndromic testing to your lab
Get in touch to learn how.
  1. Martinez, R.M, et al. Clinical Virology Symposium 2016. Poster #C-368
  2. Zhu et al., Clin Pediatr, 2019, 58(2):185-190
  3. Rappo U, et al. J Clin Micro 2016 


Data cited pertains to the use of a device from another manufacturer.

The QIAstat-Dx Analyzer is intended for in vitro diagnostic use.

The QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use.

  • This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
  • This product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
  • This emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner.